POSEIDA THERAPEUTICS INC's ticker is PSTX and the CUSIP is 73730P108. A total of 65 filers reported holding POSEIDA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,078,929 | +201.8% | 2,554,172 | +123.2% | 0.00% | +200.0% |
| Q2 2023 | $2,014,058 | +66923.6% | 1,144,351 | +17.3% | 0.00% | -50.0% |
| Q1 2023 | $3,005 | -65.6% | 975,612 | -40.8% | 0.00% | -60.0% |
| Q4 2022 | $8,729 | -98.4% | 1,646,897 | +984.9% | 0.01% | – |
| Q3 2022 | $536,000 | -79.5% | 151,798 | -85.0% | 0.00% | -100.0% |
| Q2 2022 | $2,612,000 | -30.1% | 1,012,515 | +21.3% | 0.00% | 0.0% |
| Q1 2022 | $3,739,000 | -38.8% | 834,586 | -6.9% | 0.00% | -33.3% |
| Q4 2021 | $6,105,000 | -8.0% | 896,514 | -1.5% | 0.00% | -25.0% |
| Q3 2021 | $6,633,000 | -36.7% | 909,856 | -13.0% | 0.00% | -33.3% |
| Q2 2021 | $10,482,000 | -37.8% | 1,046,123 | -40.7% | 0.01% | -50.0% |
| Q1 2021 | $16,851,000 | +4.2% | 1,764,505 | +19.7% | 0.01% | 0.0% |
| Q4 2020 | $16,176,000 | +291.0% | 1,474,529 | +216.1% | 0.01% | +140.0% |
| Q3 2020 | $4,137,000 | – | 466,459 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,043,267 | $2,692,000 | 1.92% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 380,606 | $982,000 | 0.30% |
| Pentwater Capital Management LP | 4,967,227 | $12,815,000 | 0.15% |
| Atom Investors LP | 55,827 | $144,000 | 0.06% |
| Corton Capital Inc. | 14,978 | $39,000 | 0.04% |
| Forefront Analytics, LLC | 23,370 | $61,000 | 0.03% |
| Delphia (USA) Inc. | 15,799 | $41,000 | 0.03% |
| Advisory Services Network, LLC | 259,571 | $670,000 | 0.02% |
| Laurion Capital Management LP | 545,700 | $1,408,000 | 0.02% |
| MCF Advisors LLC | 59,659 | $154,000 | 0.02% |